Analysts Set Cencora, Inc. (NYSE:COR) PT at $380.25

Shares of Cencora, Inc. (NYSE:COR) have earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $380.25.

COR has been the topic of a number of research reports. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research note on Friday, May 8th. Evercore set a $360.00 price objective on shares of Cencora in a report on Wednesday, April 8th. Finally, William Blair assumed coverage on shares of Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating for the company.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently modified their holdings of the stock. Kemnay Advisory Services Inc. bought a new position in Cencora in the 4th quarter worth about $25,000. Oakworth Capital Inc. bought a new stake in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Cencora in the fourth quarter worth about $27,000. Archer Investment Corp lifted its stake in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in shares of Cencora during the fourth quarter valued at approximately $29,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 2.5%

Shares of NYSE:COR opened at $270.12 on Friday. The firm has a market capitalization of $52.55 billion, a P/E ratio of 20.71, a P/E/G ratio of 1.42 and a beta of 0.59. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a 50 day moving average price of $293.70 and a 200-day moving average price of $330.94. Cencora has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora will post 17.79 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Cencora declared that its board has authorized a share buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.